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Abstract
Aim To report the results of a series of patients under-
going pure endoscopic endonasal pituitary surgery and to
evaluate the efficacy and safety of this procedure.
Materials and methods The data of 1,166 patients that
underwent endoscopic endonasal transsphenoidal adenoma
removal between December 2006 and June 2013 were retro-
spectively reviewed. Pre- and postoperative hormonal status
(3 months after surgery) were analyzed and compared with
the clinical parameters originally presented by the patients.
The incidences of tumor removal, hormonal control, and
tumor removal complications were retrospectively analyzed.
Result Out of 577 nonfunctioning adenomas, 180 were
growth hormone (GH) secreting, 308 prolactin (PRL) secret-
ing, 26 mixed GH/PRL adenomas, 68 adrenocorticotropin
secreting, and 7 thyroid-stimulating hormone-secreting ade-
nomas. The gross total removal of pituitary adenomas was
achieved in 98 % of microadenomas, 92 % of macroadeno-
mas, and 76 % of giant adenomas. Hormonal control was
achieved in 47 (69 %) cases of ACTH adenomas, 119 (66 %)
GH adenomas, 262 (85 %) PRL adenomas, and 6 (86 %) TSH
adenomas. Postoperative complications were observed in 168
(14.4 %) patients. The most frequent complications were
diabetes insipidus (7 %), epistaxis (1.7 %), hyposmia (1.5 %),
anterior lobe insufficiency (1.3 %) ,and CSF leaks (0.6 %).
Conclusion The pure endoscopic approach is a safe, effi-
cacious, andminimally invasive technique for the removal of
pituitary adenomas.A higher gross total resection rate is vital
for non-functional and functional adenomas. For patients
with functional adenomas, while hormonal remission is
unlikely to be achieved by surgery, the use of adjuvant
therapy is advocated to obtain long-term hormonal control.
Keywords Endoscopic surgery  Endonasal,
transsphenoidal surgery  Pituitary adenoma
Pituitary tumors, one of the most frequent intracranial
tumors, are clinically classified into 2 groups of tumors:
functioning and nonfunctioning. Successful removal of the
pituitary gland via the transsphenoidal approach was firstly
successfully described by Schloffer [1] in 1906. The sub-
labial transsphenoidal approach to sellae turcica was then
modified by Cushing in 1912 [2]. Following the introduc-
tion of the endoscope, innovative sellae, and parasellae
surgery procedures are currently implemented. The endo-
scope-guided transsphenoidal surgery was standardized in
clinical practice by Jho and Carrau [3] and Cappabianca
et al. [4], introducing enhanced illumination and visuali-
zation of the lesions. In the current study, a review of a
database of 1,166 consecutive pituitary adenomas, resected
by conventional endoscopic endonasal transsphenoidal
techniques was conducted. An analysis of the techniques,
effectiveness and morbidity of the technique for pituitary
adenomas by one doctor in a single center was conducted.
Materials and methods
A total of 1,166 pituitary adenoma patients that underwent
pure endoscopic endonasal transsphenoidal surgery, con-
ducted by the leading surgeon Zhou tao at the Neurosur-
gery Department of PLA general hospital between January
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2007 and June 2013, were retrospectively studied. All
patients underwent neurologic, ophthalmologic, and endo-
crine examinations prior to surgery. The patient follow-up
period varied from 3 months to 5.6 years.
Endocrine assessment
All endocrine examinations were performed prior to and
after surgery and at the time of follow-up consultation.
Multiple measurements of plasma growth hormone (GH),
insulin-like growth factor-I (IGF-I), prolactin (PRL),
adrenocorticotrophic hormone (ACTH), cortisol, 24 h uri-
nary free cortisol (when Cushing’s disease was suspected),
thyroid-stimulating hormone (TSH), free thyroxine,
luteinizing hormone (LH) and follicle stimulating hormone
(FSH), testosterone, and estradiol (E2) levels were
investigated.
Neuroradiology
To evaluate the size and the invasion of the adenoma, all
patients underwent magnetic resonance imaging (MRI),
with and without administration of the intravenous contrast
agent prior to surgery. Tumor size was classified in three
categories according to maximum tumor diameter: micro-
adenoma (\10 mm); macroadenomas ([10 mm); and giant
adenoma ([40 mm). Conventional paranasal computerized
tomography scans were used in 264 patients for surgical
planning. Sphenoid sinus and septal anatomy were evalu-
ated in detail. Follow-up MRI studies were obtained at 3
and 6 months following surgery.
Surgical techniques
All patients were treated by the same medical team, using
identical procedures. Under general anesthesia, the patient
was placed in the supine position on the operative table with
the back elevated at a 30 angle and the head tilted back at a
20 angle. The neurosurgeon was positioned on the right side
of the patient and the assistant on the left side. Preoperative
preparation of the nasal mucosa consists of pledgets soaked
in tetracaine HCl 20 mg/ml and epinephrine HCl
0.0125 mg/ml mix solution which are placed on medial side
of the turbinate through both nostrils for the mucosal
decongestion and to decrease mucosal bleeding during nasal
phase of surgery. Briefly, after intubation, the endoscope
(Karl Storz, Tuttlingen,Germany)was inserted into the nasal
cavity. The middle turbinate is lateralized or fractured to
promote normal postoperative middle meatus physiology. In
the reported cases, the space between the middle turbinate
and the nasal septum was gently widened. The unilateral
nostril was commonly utilized for the majority of patients,
while bilateral nostrils were utilized for patients with giant
adenomas or when the tumors were located in the sphenoid
sinus. Predominantly, in the cases reported in this study, the
right nostril approach was chosen. If the right nostril was
unsuitable due to septal deviation or adenoma extension to
the right cavernous sinus or to the superior sellae region, the
left nostril was utilized. The ostium was observed and wid-
ened to visualize entrance to the sphenoid sinus. Drilling of
the base of the sphenoid and particularly removal of the
sphenovomerine suture enabled exposure of the sellae floor
and also significantly increased the maneuverability of sur-
gical instruments, thus augmenting the efficacy and safety of
endoscopic surgery by improving accessibility to the tumor
and controlling any bleeding, similar to that achieved by
microsurgery. Inside the sphenoid sinus, exposure of the
sellae diaphragm floor from one carotid protuberance to the
other and craniocaudally from the planum sphenoidale to the
clivus was achieved. The point of attachment of the dia-
phragm sellae should not be compromisedwith dual incision,
which can be identified by preoperative MRI T2 imaging.
Intrasphenoidal septal variations and the anterior wall of the
sellae are easily evaluated by both coronal and sagittal par-
anasal CT scans preoperatively. Intercarotid distance is
measured in great care with MRI and CT scans and these
measures are rechecked intraoperatively with the aid of
designed 10 mm scaled-dissector by the leading author. In
most cases, the neuronavigation was used to identify dia-
phragm sellae, the anterior wall of the sellae and the dura
mater are opened with a highspeed drill or Kerrison rongeur.
Visualization of the sellae region was initially performed
with a 0 endoscope. If a macroadenoma was encountered
directly beneath the dura, decompression was commenced
immediately. The interior was debulked in the traditional
fashion using curettes and suction. In the current study, if a
cavity opened during surgery, the endoscope was inserted
into the cavity, allowing direct visualization of the residual
tumor. Following tumor resection, 45 angled endoscopes
were inserted into the surgical cavity to explore for any
residual tumor. In some cases, the intraoperative MRI scan
was performed to detect the residual tumor for further
resection in case of macro adenomas. For the reconstruction
of the sellae region, a small piece of Surgicel (Ethicon Ltd.,
U.K.) was placed into the sellae cavity, and Duragen (Inte-
gra, Plainsboro, NJ,USA), positioned as an overlayer graft in
the intradual space. A larger piece of Duraform was then
placed into the sinus to sustain the Duragen graft and Bio
Glue (CryoLife, Inc., Kennesaw, GA, USA), applied to fix
the graft. The expanding sponge was inserted into the win-
dow of the anterior wall of the sphenoidal sinus as a buttress
and removed 48 h after surgery. In some cases that postop-
erative CSF leakage was obvious, an external lumbar
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drainage system was applied and kept in place for 5 days
after surgery. If the postoperative CSF leakage continues, a
second dual fixation operation should be made, a combina-
tion of duraform, underlayer, and overlayer free fascia lata
grafts was placed in the sellae floor. In the 24 h after the
surgery, CT and endocrinological evaluations were con-
ducted. Hormonal assessments, identical to the preoperative
hormonal screenings,were performed onpostoperative day 1
and 7 and in the first and third postoperative months.
Results
A total of 1,166 pituitary adenomas were treated by one
surgeon in one medical center. Males and females repre-
sented 44.3 and 55.7 % of patients, respectively. The mean
age of the population was 40.3 ± 15.25 years (Table 1).
According to the size of the lesion, 245 (21.0 %) of tumors
were classified as microadenomas, 806 (69.1 %) tumors as
macroadenomas, and 115 (10 %) tumors as giant adeno-
mas. Hormone-secreting adenomas represented the major-
ity of lesions (589 cases, 50.6 %). The most common of
functioning lesions was PRL secreting pituitary adenomas
(26.4 %), followed by GH-secreting pituitary adenomas
(15.4 %), mixed GH/PRL secreting pituitary adenomas
(2.2 %), and ACTH-secreting adenomas (5.8 %), followed
by TSH secreting adenomas (0.6 %) (Table 2).
Gross total resection as ascertained by MRI results
3 months after surgery was achieved in 240 (98 %) cases
of microadenomas, 742 (92 %) cases of macroadenomas,
and 87 (76 %) cases of giant adenomas (Table 3). Visual
recovery was acquired in 105 (92 %) cases, with the III and
VI cranial nerve function restored in 22 (88 %) patients.
Hormonal control, determined in the 3 months after sur-
gery, was achieved in 47 (69 %) cases of ACTH-secreting
pituitary adenomas, 119 (66 %) cases of GH-secreting
pituitary adenomas, 262 (85 %) cases of PRL secreting
pituitary adenomas, and 6 (86 %) cases of TSH secreting
adenomas (Table 4).
Complications
Complications were observed in 157 (13.5 %) patients
(Table 5). Diabetes insipidus (DI) was observed in 82
patients following surgery, 74 of them (6.3 % of all
patients) presented with only transient dysfunction, while 8
patients presented with permanent DI, requiring vasopres-
sin therapy and clinical follow-up. Postoperative CSF
leakage was observed in 7 cases (0.6 %). A second oper-
ation was performed in these patients to reconstruct the
sellae and the double layer of duraform and free fascia lata
grafts placed in both the intradural and epidural space
supported by fat tissue. Lumbar drainage was maintained
for 5–7 days after the operation. Twelve patients that suf-
fered from meningitis were adequately treated, and
recovered well. Twenty patients suffered from postopera-
tive epistaxis, 17 of which required coagulation by packing
of the nasal cavity. One case was treated by the ENT
Table 1 Characteristics in 1,166 patients with pituitary adenomas
Characteristics N = 1,166
Gender
Male n (%) 517 (44.3)
Female n (%) 649 (55.7)
Age (years) 40.3 ± 15.25
Median follow-up period (years) 2.40 (0.25–5.60)
Table 2 General characteristics of 1,166 pituitary adenomas
Adenomas characteristics N (%)
Nonfunctioning adenomas 577 (49.5)
Hormone-secreting adenomas 589 (50.5)
GH-secreting adenomas 180 (15.4)
Prolactinoma 308 (26.4)
Mixed GH/PRL adenomas 26 (2.2)
ACTH-secreting adenomas 68 (5.8)
TSH secreting adenoma 7 (0.6)
Tumor size
Microadenomas B 10 mm 245 (21.0)
Macroadenomas B 40 mm 806 (69.1)
Giant adenomas[ 40 mm 115 (9.9)
N sample size
Table 3 Results of gross total resection of pituitary adenomas
N Gross total resection n (%)
Microadenomas 245 240 (98)
Macroadenomas 806 742 (92)
Giant adenomas 115 87 (76)
N sample size










GH 180 119 (66) 79 60
PRL 308 262 (85) 95 77
ACTH 68 47 (69) 59 71
TSH 7 7 (100) 100 None
N sample size
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colleagues, while 2 cases that did not respond to the above-
mentioned method were treated with endovascular embo-
lization of maxillary artery branches. Out of seventeen
patients that suffered from transient hyposmia, 8 patients
recovered after 3 months and 9 patients with giant non-
functioning adenoma recovered after 6 months. Fifteen
patients experienced hypopituitarism and consequently
required thyroid replacement therapy and/or steroid
replacement therapy. One patient presented with headache
and transient III cranial nerve palsy. The CT scan of this
patient showed SAH and consequently CTA was per-
formed to exclude the aneurysm. One giant non-functional
patient suffered coma after surgery and was lost when
follow-up. Eight cases of intrasellae bleeding following
surgery were observed. Evacuation of the hematoma via an
endoscopic approach was performed in 7 cases, and a third
operation was performed in one patient with residual
hematoma after second evacuation surgery. Normal visual
acuity was restored in 3 out of these 8 patients while 5
patients had poor visual acuity.
Case illustration
Five cases were listed (Table 6): 1 nonfunctioning ade-
noma (Fig. 1), 1 nonfunctioning adenoma invading cav-
ernous sinus (Fig. 2), 1 PRL adenoma (Fig. 3), 1 ACTH
adenoma (Fig. 4), and 1 TSH adenoma (Fig. 5). All the
adenomas got gross total resection.
Discussion
In recent years, endoscopic endonasal transsphenoidal
surgery has a wide application in the treatment of pituitary
adenomas. It has been used in our medical center where the
correspondence author (Doctor Zhou) of this manuscript is
since 2007 because the endoscopic surgery can provide
better vision and result in less nasal cavity injuries than the
microsurgical approach.
Exclusive endoscopic transsphenoidal resection of pitu-
itary adenomas is safe and efficacious when compared to
the traditional microscopic approach. The endoscopic
transsphenoidal approach provides a panoramic vision
inside the surgical area, a superior close up of the anatomy,
an improved working angle and less nasal cavity injuries.
D’Haens et al. [5] reported the endocrinologic outcome in 2
series of patients using these 2 different techniques, the
overall remission rate of hypersecretion was 63 % in the
endoscopic group compared to 50 % in the microsurgical
group; in noninvasive macroadenomas, the remission rate
of hypersecretion obtained using endoscopy was 78 %
compared with 43 % using microsurgery; the endocrino-
logical results achieved for microadenomas were similar in
the 2 groups; postoperative CSF leaks occurred more fre-
quently in the endoscopic group (6 cases). Strychowsky
et al. [6] made a systematic review included one prospective
and nine retrospective articles, and demonstrated that the
pure endoscopic approach was associated with less mean
blood loss, shorter hospital stays and operative times, and
fewer nasal complications, and a trend toward better gross
total resection and decreased incidence of postoperative DI.
The removal rate of pituitary adenomas is closely rela-
ted with tumor volume [7, 8], which was a predicting factor
for the surgical outcome. Compared with traditional open
or transsphenoidal microscopic methods, the endoscopic
endonasal transsphenoidal approach offers the potential for
aggressive resection via a minimal access corridor. In the
current study, the majority of tumors were macroadenomas
(69.1 %) and giant adenomas (10 %), and the gross total of
resections of macroadenomas was 92 %, which was com-
parable to the results (96 %) reported by Dehdashti et al.
[9]; the gross total of resections of giant adenomas was
76 %, which was higher than the results (47.2 %) of a
systematic review conducted by Komotar et al. [10]. The
higher gross total resection in the present study may be
attributed to the use of intraoperative MRI and neuronav-
igation during the surgery. In our medical center, the
intraoperative MRI and neuronavigation are often used
during the treatment of macroadenomas bigger than 3 cm.
After the initial resection, the intraoperative MRI scans can
be used for assessing if there is residual tumors and
determining if a second or third surgery is required for safe
resection of the lesion. The surgery should not be continued
if the tumor residue is out of reach, the access corridor is
very narrow for the operation, or when most parts of some
giant adenoma were removed to achieve the decompres-
sion. A second transcranial surgery or radiotherapy or
Table 5 Surgery complications in the 1,166 patients with pituitary
adenomas
Type of complication n (%) of patients
Transient diabetes insipidus 74 (6.35)
Permanent diabetes insipidus 8 (0.69)
Postoperative hemorrhage 8 (0.69)
CSF leak 7 (0.60)
Meningitis 12 (1.03)
Decreased visual acuity 5 (0.43)
Epistaxis 20 (1.72)
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radiosurgery may be considered for tumors invading into
cavernous sinus and neighboring cranial base that cannot
be totally removed by the first surgery.
Nonfunctioning adenomas
The main symptoms of nonfunctioning adenomas include
pituitary failure (hypopituitarism) and hemianopsia, progres-
sive loss of vision, diplopia, headaches, and so on. Generally,
nonfunctioningmicroadenomas are not suggested for surgical
treatment. But for young patients with asymptomatic mac-
roadenomas, the resection is recommended, if the suggestion
is not accepted by the patient, close follow-up is necessary.
When nonfunctioning macroadenomas produce acute intra-
tumoral hemorrhage, resulting in symptoms such as sudden
headaches, progressive loss of vision and diplopia, the
immediate decompression treatment should be performed.
Giant nonfunctioning adenomas may extend around the car-
otid artery, through the cavernous sinus, and into the temporal
lobe or suprasellarly into the third ventricle and basal cisterns.
In such cases, the transcranial surgery should be considered. If
the surgery is performed by endoscopic approach, care must
be taken not to damage the carotid artery while dealing with
the carotid artery, and not to injury the vital structures such as
Table 6 Case illustration
Gender Age (years) Type Image before and after surgery Resection Hormonal control
1 F 66 Nonfunctioning Figure 1 Gross total –
2 F 35 Nonfunctioning Figure 2 Gross total –
3 M 45 PRL Figure 3 Gross total Yes
4 F 27 ACTH Figure 4 Gross total Yes
5 M 60 TSH Figure 5 Gross total Yes
Fig. 1 MRI images of one
nonfunctioning adenoma. A,
C Before surgery, B, D gross
total resection after surgery
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the optic apparatus while dealing with the suprasellae part of
the tumor. If the nonfunctioning adenoma could not be
resected totally and are stable with no obvious symptoms in
follow-up visit, it can be for further observation [11]. If it is
developed, a second endonasal surgery or craniotomymay be
considered.
Fig. 2 MRI images of one
nonfunctioning adenoma
invading cavernous sinus. A,
C Before surgery, B, D gross
total resection after surgery
Fig. 3 MRI images of one PRL
adenoma. A, C Before surgery,
B, D gross total resection after
surgery
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Fig. 4 MRI images of
one ACTH adenoma. A,
C Before surgery, B, D gross
total resection after surgery
Fig. 5 MRI images of one TSH
adenoma. A, C Before surgery,
B, D gross total resection after
surgery
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Functioning adenomas
Both PRL and GH secreting adenomas are the most com-
mon functioning adenomas. The data from recent litera-
tures (Table 7) showed that the hormone control was
higher for PRL secreting adenomas than that for GH
secreting adenomas, and higher in microadenoma than
macroadenoma. Our results revealed the similar trend
(Table 4). Previous studies demonstrated that medical
therapy has good effect in the treatment of PRL secreting
adenomas, the patients with drug treatment had normal
menstrual cycle and got pregnant, and thus medical therapy
can be used as the preferred treatment for PRL secreting
adenomas. Surgery is recommended when patients are
intolerant to side effect of drugs, or cannot be cured by
drugs, or suffer from pituitary apoplexy. However, in
China, costs for medication are often considered, when
patients select methods for the treatment of PRL secreting
adenomas. After weighing the risk and benefit of surgery,
many patients may select surgical treatment for PRL
secreting adenomas in China. Preoperative medical therapy
can reduce the tumor size and facilitate surgery for the
giant PRL secreting adenomas.
Surgery is preferred for the treatment of GH macroad-
enomas. The normalization of hormone levels is import in
reducing the morbidity associated with tumors during the
treatment. It should be noted that the physical condition of
patients with poor cardiac function and physical condition
should be improved by drugs such as somatostatin prior to
surgery. In order to control hormone levels, tumors should
be removed as much as possible so as to decrease the size
of the adenoma for the followed medical therapy and
radiotherapy. Tumor residue is a main cause of poor con-
trol of hormone level after surgery, cavernous sinus
invasion was associated with a significantly lower remis-
sion rate in GH-secreting macroadenomas [12–15]. Ceylan
et al. [12] demonstrated that endoscopic transsphenoidal
surgery offered a wide exposure for cavernous sinus medial
wall adenomas, enabling more removal of the adenoma
from the medial cavernous sinus wall.
During the surgery for ACTH-secreting adenomas, the
poor control of hormone level is often caused by poor
visualization of lesions on preoperative MR imaging [15].
In our medical center, all the ACTH-secreting adenomas
are surgically treated. The surgery is required to incise the
adenomas while retaining the normal parenchyma of the
gland as much as possible. In cases of the exact lesion site
of ACTH-secreting adenomas invisible on preoperative
MR imaging, the surgical treatment should be based on
analysis of blood samples from preoperative inferior
petrosal sinus.
Macchia et al. [16] reported that 55 % of TSH adenoma
patients obtained remission (success rate of 40 and 67 % in
macro- and microadenomas, respectively) following sur-
gery. Pre-treatment with somatostatin analogs (SSA)
resulted in an apparent, although not statistically significant
increase in success rate in micro-, but not macroadenomas.
A varied combination of surgery, somatostatin medicine,
and radiotherapy can achieve long-term therapeutic effect
[17, 18].
Complications
Complications of the endoscopic surgery have an incidence
of 3.4–36.1 % [7, 19–27], and are mostly DI, anterior lobe
dysfunction, and CSF leak (Table 8). Temporary DI is
thought to be a result of temporary dysfunction caused by
surgical trauma, and stretching of pituitary stalk by the
Table 7 Hormonal control of
functional pituitary adenomas
resection from major
endoscopic pituitary series in
literature in the last 5 years




Hofstetter et al. [15] 2011 86 GH 75 40
PRL 92.3 57.1
ACTH 54.5 71.4





Campbell et al. [13] 2009 26 GH 75 54.5
Yano et al. [30] 2009 29 GH 87.5 65.2
PRL 94.1 41.7
Macchia et al. [16] 2009 26 TSH 67 40
Choe et al. [14] 2008 12 GH 100 87.5
ACTH 100
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falling diaphragm after the removal of the adenoma. In the
current study, all the patients with DI were cured after
treatment. The anterior temporary lobe dysfunction might
be related with operation of the pituitary gland such as the
excessive use of the aspirator in the sellae cavity, inap-
propriate manipulation and resection of the normal pitui-
tary gland neighboring the adenoma tissue, and heat
damage of bipolar coagulation in sellae cavity to pituitary
gland. Thus, hemostatic Surgicel rather than bipolar
coagulator should be used for hemostasis in vicinity of the
stalk [19]. In the macro- or giant adenoma, the pituitary
tissue thinned by compression was difficult to distinguish
from tumor and easy to be damaged when removing tumor,
or the normal pituitary lie below the tumor and was also
injured easily. Therefore, the relation between the tumor
and normal gland should be carefully identified from the
preoperative MRI image, in order to preserve the pituitary
tissue during the surgery. The scraper ring was suggested to
be used for adenoma resection because it could decrease
the injury to normal tissue and diaphragm. The angled
endoscope could be used, since it could facilitate the
detection of the residual tumor and avoid damage of pitu-
itary gland during the operation.
Attention should be paid to intraoperative CSF leakage.
Intraoperative CSF leakage could be found during or after
the tumor removal. It could occur during the exploration of
cavernous sinus and diaphragmatic recesses, and most of
them could stop without any treatment. CSF leakage fre-
quency and persistence increased in patients who had
previous surgery, or in patients with suprasellae extension
of the macroadenoma and during extended endoscopic
approaches. CSF leak risk is higher in macroadenomas than
microadenomas [25, 28], primarily due to the fact that the
surgeon works closer to the diaphragm sellae and the
subarachnoid space in these cases. Hence, it is critical to
identify the tear in the diaphragm and/or arachnoid mem-
brane during the surgery and seal it immediately [19]. In
this study, the incidence of CSF was not high probably
because (1) based on the point of attachment of diaphragma
sellae identified on MRI T2 images, the sellae was open to
a moderate extent in the anterior cranial base, avoiding
laceration of the dura mater. (2) the diaphragm was kept
intact during surgery. Macro- and giant adenomas often
extended to the diaphragm. During the surgery, the dia-
phragm sella may fall to cover the remained tumors after
parts of tumor were incised. In this case, further tumor
resection could often damage the diaphragm sella. To keep
the diaphragm intact, we identified the location of residual
tumor and its relationship with the diaphragm sella using
the intraoperative MRI scan, rescheduled the navigation. If
the residual tumor located above or behind the falling
diaphragm, the diaphragma was pushed upward in order to
resect the residual adenoma, thus preventing breakage of
the diaphragm. Rather, the surgeons chose opted removal
of the tumor by inserting the endoscope to the tumor
cavity. (3) CSF leak was repaired intraoperatively as soon
as it was detected, in these cases, a strict reconstruction
with double layer duraform is performed. Not all the CSF
leak was from the broken diaphragm. In our study, 7 cases
of CSF leakage after first surgery were reported. In the
secondary operation, it was found that the CSF leak was
from the laceration point of the dual of dorsum sellae in 2
cases, and damaged dual dorsum sellae by the infiltrating
of the tumor in 1 case. All of these 3 cases showed no CSF
leak in the first surgery. In the remaining 4 cases, the
leakage lied in the diaphragm, with 3 cases showing no
CSF leak in the first operation, and 1 case receiving repair
when leak occurred, but with the duraform found to be
leaking into the cavity following failed fixation. All the 7
cases had good outcome following the second repair.
Table 8 Complications from
endoscopic pituitary series in
literature in recent 5 years
Year N Total complication (%) Most frequent complication (%)
Berker et al. [19] 2012 570 11.3 Diabetes insipidus (4.6)
Cavallo et al. [20] 2012 59 3.4 CSF leak (1.7)
Hematoma in the tumor field (1.7)
Gondim et al. [21] 2011 301 26.9 Anterior lobe insufficiency (11.6)
De Witte et al. [22] 2011 83 36.1 Anterior lobe insufficiency (19.2)
Zada et al. [23] 2010 169 10.7 Epistaxis (3)
Diabetes insipidus (3)
Gondim et al. [29] 2010 228 13.9 CSF leak (3.1)
Charalampaki et al. [24] 2009 150 19.7 Diabetes insipidus (5.9)
Yano et al. [30] 2009 213 10.8 CSF leak (4.2)
Dehdashti et al. [7] 2008 200 9.5 CSF leak (3)
Anterior lobe insufficiency (3)
Present study 1,166 14.4 Diabetes insipidus (7)
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The syndrome of inappropriate ADH (SIADH) was low
and temporary (data not shown). Hyponatremia often
occurred 5–10 days after surgery. Patients were treated
with water restriction plus hypertonic sodium replacement.
Conclusion
The exclusive endoscopic approach is a safe, efficacious, and
minimally invasive technique for treatment of pituitary
adenoma. A higher gross total resection rate is vital for non-
functional and functional adenomas. For functional adeno-
mas, hormonal remission is unlikely to be achieved by sur-
gery alone, indicating that the use of adjuvant therapy be
introduced to obtain long-term hormonal control. The pro-
gression of endoscopy instruments, more experienced doc-
tors, and the development of more effective drugs are all
important factors for the good outcome of pituitary adenoma.
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